Anthony B Pinkerton

US Patent:

8372852, Feb 12, 2013

Filed:

May 11, 2012

Appl. No.:

13/470122

Inventors:

Alex Shaginian - San Diego CA, US
Samedy Ouk - San Diego CA, US
Jean-Michel Vernier - San Diego CA, US
Anthony B. Pinkerton - San Diego CA, US

Assignee:

Ardea Biosciences, Inc. - San Diego CA

International Classification:

C07D 473/28
C07D 473/34
A61K 31/52
A61P 31/18
C07D 487/04
A61K 31/519

US Classification:

5142632, 51426322, 51426337, 5142651, 514280, 5142621, 5142633, 544265, 544276, 544254, 544280, 544262

Abstract:

Described herein are novel enzyme inhibitors. In some embodiments, the enzyme inhibitors are reverse transcriptase inhibitors, particularly HIV reverse transcriptase inhibitors. Also described herein are compositions containing them and methods of using them. Thus, the compounds and compositions described herein are useful for the in vitro and in vivo inhibition of HIV reverse transcriptase as a method of treating or preventing HIV, AIDS or related disorders. In some embodiments, the enzyme inhibitors are compounds of formula (I) or a pharmaceutically acceptable salt or tautomer thereof:.

US Patent:

8207178, Jun 26, 2012

Filed:

Dec 12, 2008

Appl. No.:

12/334371

Inventors:

Alex Shaginian - San Diego CA, US
Samedy Ouk - San Diego CA, US
Jean-Michel Vernier - San Diego CA, US
Anthony B. Pinkerton - San Diego CA, US

Assignee:

Ardea Biosciences, Inc. - San Diego CA

International Classification:

C07D 487/04
A61K 31/519
A61P 31/18
C07D 473/30
A61K 31/52

US Classification:

5142651, 544280, 544262, 544254, 544265, 5142621, 5142611, 51426322, 5142633

Abstract:

Described herein are novel enzyme inhibitors. In some embodiments, the enzyme inhibitors are reverse transcriptase inhibitors, particularly HIV reverse transcriptase inhibitors. Also described herein are compositions containing them and methods of using them. Thus, the compounds and compositions described herein are useful for the in vitro and in vivo inhibition of HIV reverse transcriptase as a method of treating or preventing HIV, AIDS or related disorders. In some embodiments, the enzyme inhibitors are compounds of formula (I) or a pharmaceutically acceptable salt or tautomer thereof:.

US Patent:

20050288346, Dec 29, 2005

Filed:

Aug 22, 2003

Appl. No.:

10/524704

Inventors:

Rowena Cube - San Diego CA, US
Anthony Pinkerton - San Diego CA, US
Jean-Michel Vernier - San Diego CA, US
Xiumin Zhao - San Diego CA, US

International Classification:

A61K031/41
C07D257/02

US Classification:

514381000, 548253000

Abstract:

The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

US Patent:

20070049591, Mar 1, 2007

Filed:

Aug 24, 2006

Appl. No.:

11/509508

Inventors:

Anthony Pinkerton - San Diego CA, US
Robert Davis - Carlsbad CA, US
Timothy Gahman - Encinitas CA, US
J. Semple - San Diego CA, US

International Classification:

A61K 31/5377
A61K 31/522
A61K 31/52
A61K 31/519
A61K 31/503
C07D 487/02
C07D 473/02

US Classification:

514234500, 514248000, 514262100, 514263300, 514263400, 514267000, 544235000, 544276000, 544277000, 544250000, 544262000

Abstract:

The present invention relates to compounds useful as inhibitors of MEK kinase and methods for the treatment or prevention of cellular proliferative disease states, such as conditions related to the hyperactivity of MEK, as well as diseases modulated by the MEK cascade.

US Patent:

20080096935, Apr 24, 2008

Filed:

Oct 21, 2005

Appl. No.:

11/666072

Inventors:

Anthony Pinkerton - San Diego CA, US
Jean-Michel Vernier - San Diego CA, US
Rowena Cube - Somerset PA, US
John Hutchinson - La Jolla CA, US

International Classification:

A61K 31/4412
A61K 31/4196
A61K 31/4152

US Classification:

514345000, 514408000, 514406000, 514383000, 546290000, 548263200, 548571000, 548373100

Abstract:

The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

US Patent:

20080167322, Jul 10, 2008

Filed:

Feb 14, 2006

Appl. No.:

11/884325

Inventors:

Anthony B. Pinkerton - San Diego CA, US
Rowena Cube - Harleysville PA, US
John Hutchinson - La Jolla CA, US
Dehua Huang - San Diego CA, US
Jean-Michel Vernier - San Diego CA, US

International Classification:

A61K 31/497
C07D 231/10
A61K 31/4155
A61P 19/02
C07D 401/02
A61K 31/4439

US Classification:

51425505, 5483701, 514407, 514341, 5462761, 544405

Abstract:

Substituted pyrazole compounds such compounds represented by formula I: which are used to modulate the CCR-2 chemokine receptor to prevent or treat inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis; and pharmaceutical compositions comprising these compounds and the use of these compounds and compositions.

US Patent:

20080221161, Sep 11, 2008

Filed:

Feb 5, 2008

Appl. No.:

12/026315

Inventors:

Anthony B. Pinkerton - San Diego CA, US
Ayman Kabakibi - San Diego CA, US
Mark R. Herbert - San Diego CA, US
Dana Siegel - San Diego CA, US

Assignee:

KALYPSYS, INC. - San Diego CA

International Classification:

A61K 31/4725
C07D 215/00
A61P 3/00

US Classification:

514314, 546177

Abstract:

Disclosed herein are compounds useful as modulators of TGR5 and methods for the treatment or prevention of metabolic, cardiovascular, and inflammatory diseases.

US Patent:

20080293684, Nov 27, 2008

Filed:

Jul 26, 2005

Appl. No.:

11/658546

Inventors:

Anthony B Pinkerton - San Diego CA, US
Jean-Michel Vernier - Laguna Niguel CA, US
Rowena V. Cube - Harleysville PA, US
John H. Hutchinson - La Jolla CA, US
Dehua Huang - San Diego CA, US
Celine Bonnefous - San Diego CA, US
Steven P. Govak - San Diego CA, US
Theodore Kamenecka - Palm Beach Gardens FL, US

International Classification:

A61K 31/397
C07D 311/02
A61K 31/353
A61K 31/12
C07C 49/213
C07D 211/72
A61K 31/44
A61K 31/505
C07D 239/02
C07D 217/22
A61K 31/472
A61K 31/497
C07D 401/02
C07D 213/24
A61K 31/4427
C07D 471/04
A61K 31/437
A61K 31/4245
A61P 25/08
A61P 25/24
A61P 25/18
C07D 213/62
A61K 31/444
A61K 31/343
C07D 307/77
C07D 473/28
A61K 31/522
A61K 31/41
C07D 257/04
C07D 263/58
A61K 31/423
A61K 31/428
C07D 277/20
C07D 205/02
C07D 271/10
C07D 215/58
A61K 31/47
C07D 403/02
C07D 417/02
A61K 31/427

US Classification:

51421001, 549402, 514457, 514679, 568325, 546301, 514345, 514274, 544318, 546146, 514307, 51425301, 544360, 546334, 514357, 514338, 5462734, 546118, 514303, 514364, 548143, 546153, 514312, 51425214, 544295, 548181, 514365, 548950, 548170, 514367, 514375, 548221, 548251, 514381, 5142633, 544265, 549471, 514469, 514335, 546261

Abstract:

The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.